

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **SINGLE DOSE PRE-FILLED SYRINGE**

#### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nobivac Respira Bb suspension for injection in pre-filled syringe for dogs

#### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dose (1 ml) contains:

**Active substance:**

*Bordetella bronchiseptica* fimbriae<sup>1</sup>: 88 - 399 U<sup>2</sup>

<sup>1</sup> Purified from strain Bb7 92932

<sup>2</sup> Antigenic mass ELISA units

**Adjuvant:**

dl- $\alpha$ -tocopheryl acetate: 74.7 mg

For the full list of excipients, see section 6.1.

#### **3. PHARMACEUTICAL FORM**

Suspension for injection in pre-filled syringe.

Aqueous, white to nearly white suspension, mild creaming.

#### **4. CLINICAL PARTICULARS**

##### **4.1 Target species**

Dogs.

##### **4.2 Indications for use, specifying the target species**

For active immunisation of dogs against *Bordetella bronchiseptica* to reduce clinical signs of upper respiratory tract disease and bacterial shedding post infection.

Onset of immunity: 2 weeks.

Duration of immunity: 7 months after primary vaccination.  
1 year after re-vaccination.

##### **4.3 Contraindications**

None.

##### **4.4 Special warnings for each target species**

Vaccinate healthy animals only.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

Not applicable.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Not applicable.

#### **4.6 Adverse reactions (frequency and seriousness)**

A transient swelling at the site of injection ( $\leq 2$  cm), which can occasionally be firm, may very commonly be present for up to 25 days post-vaccination. A medium size transient swelling at the site of injection ( $\leq 3.5$  cm) may occur in common cases and can be painful. The swelling may uncommonly last for up to 35 days post-vaccination.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Can be used during pregnancy. The safety of this vaccine has not been investigated during the first 20 days of gestation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Safety and efficacy data are available which demonstrate that this Nobivac Respira Bb vaccine can be administered at the same time but not mixed with the live vaccines of the Nobivac series against canine distemper, canine contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2, where authorized.

Safety data are available which demonstrate that this Nobivac Respira Bb vaccine can be administered at the same time but not mixed with the Nobivac series of vaccines mentioned above together with the live Nobivac parainfluenza vaccine and the inactivated vaccines of the Nobivac series against leptospirosis caused by *L. interrogans* serogroup Canicola serovar Canicola, *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni, *L. interrogans* serogroup Australis serovar Bratislava, and *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Lianguang.

In addition, for the live canine parainfluenza vaccine antibody response data, and for the inactivated canine leptospirosis vaccines antibody response data and other immunity data support the use of the Nobivac Respira Bb vaccine at the same time but not mixed with the mentioned Nobivac series of vaccines.

When this vaccine is administered in association with the relevant Nobivac vaccines, the demonstrated safety and efficacy claims of Nobivac Respira Bb are the same as when this vaccine is administered alone.

The product information of the relevant Nobivac vaccines used in association with this vaccine should be consulted before administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

Subcutaneous use, 1 ml dose per vaccination.  
Dogs can be vaccinated from the age of 6 weeks onwards.

Allow the vaccine to reach room temperature (15°C - 25°C) before use.

##### Primary vaccination:

Two vaccinations with an interval of 4 weeks.

##### Re-vaccination:

A single vaccination, administered 7 months after primary vaccination with this vaccine, is sufficient to maintain protection against *Bordetella bronchiseptica* for a further year. Thereafter, a single vaccination should be administered, annually. In case re-vaccination at 7 months is missed, a single vaccination within 12 months after primary vaccination is sufficient to extend protection against *Bordetella bronchiseptica* for a further year.

This vaccine can also be used for re-vaccination in a schedule where Nobivac KC has been used for primary vaccination. A single vaccination, administered one year after primary vaccination with Nobivac KC, is sufficient to prolong immunity against *Bordetella bronchiseptica* for another year.

##### Re-vaccination after primary vaccination with Nobivac KC:

One vaccination, annually.

##### For associated use:

When this vaccine is administered in associated use (i.e. not mixed) with another vaccine of the Nobivac series as indicated under section 4.8, the vaccines should be given subcutaneously at the same time, at a different site. Dogs should not be younger than the minimum age recommended for the other Nobivac vaccine, as stated in the respective product information.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Not applicable.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Immunologicals for canidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)  
ATCvet code: QI07AB03.

The subunit vaccine stimulates active immunity against *Bordetella bronchiseptica* infection in dogs.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

dl- $\alpha$ -tocopheryl acetate  
Sodium chloride  
Disodium hydrogen phosphate dihydrate  
Sodium dihydrogen phosphate dihydrate  
Polysorbate 80  
Water for injections

### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

### **6.4 Special precautions for storage**

Store in a refrigerator (2°C – 8°C). Do not freeze.  
Store in the original package in order to protect from light.

### **6.5 Nature and composition of immediate packaging**

Type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.

#### Pack sizes:

Cardboard box with:

- 5 single dose pre-filled syringes (5 x 1 ml) and needles.
- 10 single dose pre-filled syringes (10 x 1 ml) and needles.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

MSD Animal Health UK Limited  
Walton Manor, Walton  
Milton Keynes  
Buckinghamshire  
MK7 7AJ

**8. MARKETING AUTHORISATION NUMBER**


Vm 01708/3002

**9. DATE OF FIRST AUTHORISATION**

18 August 2020

**10. DATE OF REVISION OF THE TEXT**

May 2022

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 12 May 2022